GlycoNex, a clinical-stage biotechnology company developing glycan-directed cancer immunotherapies, has secured a major regulatory green light in Japan, clearing the path for its lead program GNX1021 to enter first-in-human testing.

 

The Pharmaceuticals and Medical Devices Agency (PMDA) has approved initiation of a Phase 1 clinical trial of GNX1021, an antibody-drug conjugate (ADC) being developed for patients with advanced gastrointestinal cancers. 

 

The decision marks a pivotal transition for GlycoNex as it moves from preclinical development into human studies for its glycan-targeting ADC platform.

 

The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy, while also determining a recommended dose range for later-stage development. 

 

The trial will begin in Japan and Taiwan, with patient enrollment in Japan expected to start in June 2026. GlycoNex also plans to submit an Investigational New Drug (IND) application in Taiwan in June 2026, with enrollment there projected for the third quarter of 2026.

 

“PMDA approval to initiate our first-in-human study is a defining milestone for GlycoNex and a critical validation of our glycan-targeting platform,” said Dr Mei-Chun Yang, Chief Executive Officer of GlycoNex. 

 

“GNX1021 represents a differentiated approach to ADC development, designed to address tumor heterogeneity by targeting glycan structures broadly expressed across multiple cancer-associated proteins. We believe this unique mechanism, combined with the selective expression of the bLeB/Y antigen in gastrointestinal tumors, positions GNX1021 to potentially deliver meaningful clinical benefit, particularly in gastric cancer where new treatment options are urgently needed.”

 

GNX1021 is designed to go beyond conventional precision oncology approaches. Instead of targeting a single protein epitope, the ADC binds to branched glycan antigens that are abnormally overexpressed on tumor cell surfaces, enabling multi-target engagement across different cancer-associated proteins.

 

The therapy specifically targets the bLeB/Y antigen, highly expressed in epithelial tumors such as gastric, pancreatic, and colorectal cancers, while showing minimal expression in healthy tissue. This selectivity is intended to improve tumor targeting while reducing off-tumor toxicity and enhancing the therapeutic index.

 

Preclinical studies in rats and cynomolgus monkeys showed a controlled and predictable safety profile, with no significant drug accumulation or unexpected damage to major organs. These findings supported advancement into human trials, providing key validation of GNX1021’s biosafety profile.

 

Dr. Yang added: “We are encouraged by continued global interest in novel ADCs with differentiated targets. As GNX1021 advances through clinical development, we believe it has the potential to generate significant strategic partnering interest while, more importantly, advancing a new therapeutic approach for patients with difficult-to-treat cancers. 

 

"Reflecting on recent global ADC licensing trends, drugs with unique targets that have reached Phase 1 clinical trials often command total deal values ranging from several hundred million to over a billion USD.”

 

GlycoNex said the milestone positions GNX1021 as both a scientific and commercial catalyst for the company as it enters the clinical stage, with gastrointestinal cancers—particularly gastric cancer—remaining areas of high unmet medical need.